Every material Form 8-K Attovia Therapeutics, Inc. has filed with the SEC since September 02, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Attovia Therapeutics reported third quarter 2026 results on November 9, 2026, with a net loss of $22.3 million, up from $13.8 million a year earlier, and no collaboration revenue compared with $0.4 million in the prior-year quarter. The company also disclosed 12-week Phase 1b data for ATTO-1310 in chronic pruritus and high-itch atopic dermatitis, and said it expects two Phase 2 trials to start in the first half of 2027. Cash, cash equivalents, and marketable securities of $395.9 million are expected to fund operations into 2030.
Net loss was $22.3 million for Q3 2026, compared with $13.8 million for Q3 2025.
Collaboration revenue was zero in Q3 2026, compared with $0.4 million in Q3 2025.
Research and development expenses rose to $20.3 million from $12.3 million, driven by ATTO-1310 and preclinical programs.
At Week 12 in chronic pruritus patients, 82% of ATTO-1310-treated patients achieved PP-NRS4 vs. 22% with placebo; Phase 2 ATTUNE trials are on track to start in the first half of 2027.
Attovia Therapeutics reported a second quarter 2026 net loss of $20.7 million, up from $14.4 million a year earlier, as research and development expenses rose to $18.9 million. The company recorded $0.5 million of collaboration revenue, compared with none in the prior-year quarter. The company said its cash, plus about $305.4 million of net proceeds from its August 2026 IPO, will fund operations into 2030.
Net loss of $20.7 million for the quarter ended June 30, 2026, vs. $14.4 million a year earlier; net loss per share of $4.88 vs. $3.71
Collaboration revenue of $0.5 million, vs. none in Q2 2025, tied to the EndPath RadioTherapeutics license agreement
R&D expenses of $18.9 million vs. $13.6 million; G&A expenses of $3.3 million vs. $3.0 million
Cash, cash equivalents and marketable securities of $115.1 million at June 30, 2026, vs. $152.3 million at December 31, 2025; IPO net proceeds of about $305.4 million
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Attovia Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →